Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCNEC-ALPINE
2024-515902-15-00Phase 2Authorised
- Sponsor
- Technische Universität Dresden
- Start
- Oct 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab, carboplatin, cisplatin and etoposide in Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC), sponsored by Technische Universität Dresden. Primary endpoint: Overall Survival. Planned start Oct 2024; status: authorised.
02
Drugs
atezolizumabcarboplatincisplatinetoposide
03
Conditions
Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC)
Beyond the preview
Go deeper on 2024-515902-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515902-15-00.